U.S. Markets closed
  • S&P 500

    4,145.19
    -6.75 (-0.16%)
     
  • Dow 30

    32,803.47
    +76.67 (+0.23%)
     
  • Nasdaq

    12,657.55
    -63.04 (-0.50%)
     
  • Russell 2000

    1,921.82
    +15.36 (+0.81%)
     
  • Crude Oil

    88.53
    -0.01 (-0.01%)
     
  • Gold

    1,792.40
    -14.50 (-0.80%)
     
  • Silver

    19.86
    -0.26 (-1.30%)
     
  • EUR/USD

    1.0185
    -0.0065 (-0.6315%)
     
  • 10-Yr Bond

    2.8400
    +0.1640 (+6.13%)
     
  • Vix

    21.15
    -0.29 (-1.35%)
     
  • GBP/USD

    1.2070
    -0.0088 (-0.7266%)
     
  • USD/JPY

    134.9700
    +1.9540 (+1.4690%)
     
  • BTC-USD

    23,211.14
    +20.93 (+0.09%)
     
  • CMC Crypto 200

    533.20
    -2.02 (-0.38%)
     
  • FTSE 100

    7,439.74
    -8.32 (-0.11%)
     
  • Nikkei 225

    28,175.87
    +243.67 (+0.87%)
     

Shares of Xencor Could Be Bought on a 50% Correction

·2 min read
Shares of Xencor Could Be Bought on a 50% Correction
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Xencor , with its protein engineering platform, is "developing a broad pipeline of drug candidates that are optimized to treat patients with cancer and autoimmune disorders". In this daily bar chart of XNCR, below, we can see that prices quickly rebounded in June after a decline from early January. XNCR is in "striking distance" of the 200-day line now.